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Abstract
BACKGROUND
Liver stiffness measurement (LSM) tends to overestimate fibrosis stage in
nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter
(CAP), provided by LSM device, has been introduced for noninvasive
quantification of hepatic steatosis.
AIM
To determine the role of CAP values in predicting liver fibrosis stage by LSM in
nonalcoholic steatohepatitis (NASH).
METHODS
One hundred eighty-four patients with biopsy proven NASH had LSM and CAP
evaluated at baseline. Among them, 130 patients had 1-year follow up LSM and
analyzed for the changes of LSM after pioglitazone or ursodeoxycholic acid
(UDCA) treatment.
RESULTS
In Kleiner fibrosis stage F0-1, LSM values increased at higher CAP tertile (P =
0.001), and in F2, at middle and higher tertiles (P = 0.027). No difference across
CAP tertiles was noticed in F3-4 (P = 0.752). Receiver operating characteristic
curve for LSM cutoff in diagnosis of F ≥ 2 identified 8.05 kPa for lower CAP
tertile, 9.35 kPa for middle, and 10.55 kPa for high tertile. When changes in
proportion of significant fibrosis (F ≥ 2) were assessed among pioglitazone and
UDCA treated patients considering CAP values, pioglitazone treated patients
demonstrated decrease in proportion of high LSM.
CONCLUSION
In patient with NAFLD, interpretation of LSM in association with CAP scores
may provide helpful information sparing unnecessary liver biopsy.
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Core tip: Liver stiffness measurement (LSM) is said to be exaggerated in nonalcoholic
fatty liver disease (NAFLD). We investigated the role of controlled attenuation
parameter (CAP), a means of measuring steatosis noninvasively, in predicting liver
fibrosis by LSM in 184 biopsy proven nonalcoholic steatohepatitis patients. The
optimum LSM cutoff for Kleiner fibrosis stage (F) ≥ 2 reflecting CAP values showed
higher cutoff with increased CAP tertile (LSM, 8.05 kPa for lower CAP tertile, 9.35 kPa
for middle, 10.45 kPa for high CAP tertile). Therefore, we suggest that interpretation of
LSM in patients with NAFLD should take CAP scores into account in order to avoid
unnecessary liver biopsy.
Citation: Lee JI, Lee HW, Lee KS. Value of controlled attenuation parameter in fibrosis
prediction in nonalcoholic steatohepatitis. World J Gastroenterol 2019; 25(33): 4959-4969
URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4959.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i33.4959
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver
disease around worldwide. The spectrum of NAFLD ranges from simple steatosis
without  evidence of  liver  injury to  nonalcoholic  steatohepatitis  (NASH) with or
without liver fibrosis[1].  Although the natural  history of NAFLD requires further
investigation,  studies  demonstrate  that  the  severity  of  liver  fibrosis  is  the  most
important  determinant  of  mortality  and  morbidity  in  patients  with  NAFLD[2-4].
Patients with significant liver fibrosis [Kleiner classification fibrosis stage (F) ≥ 2]
showed decreased survival compared to those with no or minimal fibrosis (F0-1)[4].
NAFLD may progress from simple steatosis to NASH with fibrosis, and estimation of
severity of liver fibrosis is critical not only for the initial workup but also for follow-
up[5].
Although liver biopsy is considered the gold standard for assessing the severity of
fibrosis[6],  it  is  an  invasive  procedure  that  might  not  be  practical  to  perform
sequentially. Instead, the liver stiffness measurement (LSM), obtained by transient
elastograpy (TE) is a useful noninvasive means of assessing liver fibrosis. LSM values
are well correlated with the biopsy determined severity of fibrosis[7-9]. However, the
diagnostic performance of LSM is known to be affected by obesity and the severity of
steatosis, which are closely associated with NAFLD, resulting in overestimation of the
LSM  in  patients  with  NAFLD[10-12].  Recently,  FibroScan,  a  type  of  TE,  has  been
equipped  with  controlled  attenuation  parameter  (CAP),  software  to  enable
noninvasive  quantification  of  hepatic  steatosis.  The  CAP  value  was  strongly
correlated with the histologically assessed percentage of liver fat in patients with
NAFLD, but is susceptible to interference by liver fibrosis[13].  However, CAP may
enhance the accuracy of TE measured LSM in patients with NAFLD[14]. We evaluated
the role  of  the CAP value in predicting the liver  fibrosis  stage based on LSM in
patients with biopsy proven NASH.
MATERIALS AND METHODS
Study design
This retrospective study involved patients with biopsy proven NASH evaluated at
Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic
of Korea. Liver biopsy was performed to confirm the diagnosis of NASH in patients
with ultrasound findings of fatty liver and persistent (> 6 mo) elevation of the alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) level without excessive
alcohol consumption (30 g/day in men and 20 g/day in women). Patients in whom
liver stiffness was evaluated within 1 mo before the liver biopsy were included in the
analysis. The exclusion criteria were as follows: (1) Liver disease of other or mixed
WJG https://www.wjgnet.com September 7, 2019 Volume 25 Issue 33
Lee JI et al. CAP in liver stiffness of NASH
4960
etiology  (such  as  hepatitis  B  infection,  hepatitis  C  infection,  alcohol  abuse,
autoimmune liver disease, Wilson’s disease, or drug-induced liver disease); (2) LSM
evaluated while the AST or ALT level was more than fivefold the upper limit of
normal (ULN); (3) Hepatocellular carcinoma; (4) Advanced liver cirrhosis (Child-
Turcotte-Pugh B and C); (5) Previous treatment with steatosis-inducing drugs such as
tamoxifen,  aromatase  inhibitor,  valproic  acid,  amiodarone  or  corticosteroid;  (6)
Human immunodeficiency virus infection; (7) Active intravenous drug addiction or
use of cannabis; and (8) Insufficient clinical data.
This study was performed in accordance with the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of
Gangnam Severance Hospital (permit no: 3-2019-0010). The requirement for written
informed consent was exempted by the IRB since the database was accessed only for
analysis purposes and the patients’ personal information was anonymized by coding.
Clinical assessment
Demographic, clinical and anthropometric data were collected at the time of liver
biopsy. Hypertension was defined as use of antihypertensive medication and type 2
diabetes mellitus was considered present if the fasting glucose level was ≥ 126 mg/dL
or antidiabetic agents were being used. Body mass index (BMI) was calculated as
body weight in kilogram divided by the square of height in meters, and a BMI ≥ 25
kg/m2 was considered to indicate obesity based on the criteria used in the Asian-
Pacific region[15].
Liver stiffness measurement
TE was performed using a FibroScan (Echosens, Paris, France), medical device, with a
standard probe. Only LS values with at least 10 valid measurements, a success rate of
at least 60%, and an interquartile range-to-median ratio of < 30% were considered
reliable, as suggested by previous studies[16,17]. In addition, patients in whom LS was
measured while the AST or ALT > 5 × ULN was present, were excluded from the
analysis  due  to  possible  exaggerated  LSM  values  as  previous  studies
demonstrated[18,19]. The baseline LSM was obtained within 1 month before liver biopsy.
The follow-up LSM was performed after 12 mo of NASH treatment with daily dose of
15 mg pioglitazone, peroxisome proliferator-activated receptor (PPAR)-γ agonist, or
300 mg/day ursodeoxycholic acid (UDCA) following liver biopsy.
Histologic assessment
A  single  liver-dedicated  expert  pathologist,  blinded  to  the  patients’  identity,
performed the histologic analysis. A ≥ 15-mm-long biopsy specimen or the presence
of at least 10 complete portal tracts was considered adequate for the analysis[20]. NASH
was diagnosed according to the NASH Clinical Research Network System, and was
defined as the presence of ≥ 5% hepatic steatosis and inflammation with hepatocyte
injury such as ballooning with or without fibrosis[21].
Statistical analysis
All statistical tests were performed using IBM SPSS Statistics 22.0 (IBM, Armonk, NY,
United States). Continuous variables are expressed as means ± standard deviation
(SD) or medians (range). The area under the receiver-operating characteristic (ROC)
curve was calculated to reflect the overall accuracy of LSM for diagnosing significant
fibrosis (F2-4). Categorical variables were compared by using two-sided χ2-test (or
Fisher’s exact test, or McNemar test, as appropriate) and continuous variables by
independent or Mann-Whitney test as appropriate. A paired t test was performed to
evaluate changes in LSM. A two-sided P value of < 0.05 was considered indicative of
statistical significance.
RESULTS
Patients
From January 2010 to December 2017, 325 patients underwent liver biopsy and LSM
assessed due to suspicion of NASH. Among them, 184 patients met the inclusion and
exclusion criteria and were thus included in the analysis. The baseline characteristics
of the 184 patients with NASH are listed in Table 1.
Assessment of steatosis using CAP
Among  the  184  patients  with  biopsy  proven  NASH,  the  distribution  of  the
histologically assessed steatosis grade (S) was as follows: S1, n = 44 (2.9%); S2, n = 81
(44.0%); S3, n  = 59 (32.1%) (Figure 1). The CAP scores were significantly different
between S1 and S2-S3 (P < 0.001). However, no significant difference was detected
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Table 1  Demographic, clinical, biochemical and histological characteristics of 184 patients with
nonalcoholic steatohepatitis
Variable NAFLD (n = 184)
Age (yr) 44.6 ± 14.5
Male gender 127 (69.0%)
Body mass index, median (range, kg/m2) 29.3 (19.8-44.5)
Body mass index ≥ 25 kg/m2 156 (84.8%)
Diabetes 69 (37.5%)
Hypertension 54 (29.3%)
Hyperlipidemia 75 (40.8%)
Fasting glucose (mg/dL) 117.9 ± 32.9
HDL cholesterol (md/dL) 47.1 ± 11.8
Triglycerides (mg/dL) 193.8 ± 127.5
LDL cholesterol (mg/dL) 131.7 ± 31.3
Alanine aminotransferase (U/L) 92.4 ± 68.1
Aspartate aminotransferase (U/L) 67.3 ± 39.2
Gamma glutamyltransferase (U/L) 74.1 ± 86.7
Platelet (× 1000/mm3) 244.8 ± 58.6
Albumin (g/dL) 4.5 ± 0.3
Liver stiffness (kPa) 10.9 ± 4.9
Stiffness IQR (kPa) 1.8 ± 3.3
CAP (dB/m) 320.9 ± 37.1
Lower tertile 223-310
Middle tertile 311-339
Higher tertile 340-400
CAP IQR (dB/m) 24.7 ± 9.5
Histology at biopsy
Steatosis grade
1 (5%-33%) 44 (23.9%)
2 (34%-66%) 81 (44.0%)
3 (> 66%) 59 (32.1%)
Stage of fibrosis (Kleiner)
0 20 (10.9%)
1 84 (45.7%)
2 53 (28.8%)
3 21 (11.4%)
4 6 (3.3%)
Data are expressed as the mean ± standard deviation, median (range) or number (%). HDL: High-density
lipoprotein; LDL: Low-density lipoprotein; CAP: Controlled attenuation parameter; IQR: Interquartile range;
NAFLD: Nonalcoholic fatty liver disease.
between S2 and S3 (P = 0.075). The ROC curve showed the optimum CAP cutoff for ≥
S2 was 313.5 dB/m [area under the curve (AUC), 0.736; sensitivity, 72.9%; specificity,
63.6%]. On the other hands, the accuracy dropped to an AUC of 0.656 for S3, with a
cutoff of 323.5 dB/m (sensitivity 64.4%; specificity 55.2%).
Factors associated with LSM
LSM significantly increased with the histologically detected fibrosis stage (F0, 7.5 ±
2.1; F1, 9.8 ± 2.7; F2, 11.8 ± 4.9; F3, 15.4 ± 6.9; and F4, 20.3 ± 8.8 kPa) (P < 0.001). The
ROC curve showed that the optimum LSM cutoff for ≥ F2 was 8.95 kPa (AUC, 0.730;
sensitivity,  72.5%;  specificity,  65.4%).  According  to  univariate  and multivariate
analyses, the CAP values and pathologically detected fibrosis stage was significantly
associated with LSM (Table 2).
Although there were significant differences in CAP scores between S1 and S2-S3, no
cutoff could differentiate S3 from S2. S2 and S3 accounted for the majority of the
patients (76.1%, 140/184). Furthermore, in a multivariate analysis, the CAP value, but
not the pathologically detected steatosis grade, was associated with LSM. Therefore,
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Figure 1
Figure 1  Distribution of controlled attenuation parameter scores according to histologically assessed
steatosis grades (S). CAP: Controlled attenuation parameter.
the  variations  in  the  LSM  value  for  each  stage  of  liver  fibrosis  was  evaluated
according to arbitrary CAP tertiles (lower, 223-310; middle, 311-339; high 340-400
dB/m) (Figure 2). For F0-1, LSM values significantly increased at high CAP tertile (P =
0.001) (Figure 2A). For F2, LSM values were higher for the middle and high CAP
tertiles (P = 0.027) (Figure 2B). However, the LSM values did not differ significantly
according to CAP tertile in patients with NASH and advanced fibrosis (F3-4) (P =
0.752) (Figure 2C).
When cutoff of 8.95 kPa was used to diagnose significant fibrosis (F ≥ 2), positive
predictive values in lower, middle and high CAP tertiles was 21/31 (67.7%), 19/32
(59.4%) and 23/49 (46.9%), respectively. False positive rates increased with increasing
CAP tertile (Figure 3A). However, when different cutoffs were used for each CAP
tertile, differences in false positive rates among different CAP tertile were reduced
and the false positive rate in high CAP tertile decreased (Figure 3B). ROC curves
showed that the optimum LSM cutoff for diagnosis of F ≥ 2 was 8.05 kPa (AUC, 0.682;
sensitivity, 73.5%; specificity 51.7%) for the lower CAP tertile, LSM of 9.35 kPa (AUC,
0.843; sensitivity, 90.5%; specificity 71.8%) for the middle CAP tertile, and LSM of
10.55 kPa (AUC 0.682; sensitivity, 76.0%; specificity 52.8%) for high CAP tertile.
Effect of PPAR-γ agonist on follow up LSM
Among the 184 patients with biopsy proven NASH, 130 patients had LS measured 1
year  after  liver  biopsy  and were  treated  with  PPAR-γ  agonist  (pioglitazone)  15
mg/day  (n  =  80)  or  UDCA  300  mg/day  (n  =  50).  Regarding  the  baseline
characteristics, there was no significant difference in BMI, LS value or CAP score
between the two groups (Table 3). However, the pioglitazone group had higher rates
of DM and hypertension (P = 0.048, P = 0.049, respectively).
The patients treated with pioglitazone demonstrated a decreased LSM value after
1- year of treatment (P < 0.001), when that in UDCA-treated patients did not change
significantly (P = 0.068) (Figure 4). The CAP values did not show significant changes
after treatment with pioglitazone (318.2 ± 37.9 vs 313.2 ± 41.5 dB/m, P = 0.197) or
UDCA (319.3 ± 37.1 vs 309.2 ± 38.2 dB/m, P = 0.057). Changes in the proportion of
patients with LSM suggesting significant fibrosis (F ≥ 2) were assessed separately in
the pioglitazone and UDCA groups according to the LSM cutoffs for each CAP tertile,
that were obtained from the analysis with 184 patients. Among the patient with lower
CAP tertile (223-309 dB/m), those treated with pioglitazone showed a decreased
proportion of high LSM values (F ≥ 2) but the proportion of high LSM values did not
change significantly among the patients treated with UDCA (Figure 4A). Similar
results were noted in patients with middle (310-332 dB/m) and high CAP tertile (333-
400 dB/m) (Figure 4B and C).
DISCUSSION
This study of 184 patients with biopsy proven NASH demonstrated that high CAP
scores are associated with increased LSM values at the same fibrosis stage, resulting in
overestimation of  liver  fibrosis.  Lower  positive  predictive  values  were  noted in
patients in the high CAP tertile, particularly those with F0-2. Therefore, higher LSM
cutoffs might be useful for identifying significant fibrosis in patients with NAFLD and
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Table 2  Univariate and multivariate analysis of factors associated with liver stiffness
measurements as continuous variable in 184 patients with nonalcoholic steatohepatitis by linear
regression analysis
Univariate analysis Multivariate analysis
Variable β SE P β SE P
Age (yr) 0.053 0.025 0.037a 0.017 0.022 0.451
Male gender 0.957 0.792 0.228
BMI (kg/m2) -0.032 0.083 0.700
CAP (dB/m) 0.022 0.010 0.026a 0.041 0.009 < 0.001b
LS IQR (kPa) 0.329 0.109 0.003b 0.294 0.022 0.451
Histology at biopsy
Steatosis -0.895 0.490 0.069 -0.532 0.445 0.233
Lobular inflammation 1.134 0.082 0.152 0.776
1.366 0.650 0.008b 0.638 0.532 0.131
Ballooning 2.769 0.509 < 0.001b 2.665 0.421 < 0.001b
Fibrosis 0.331 0.344
aP < 0.05;
bP < 0.01. SE: Standard error; BMI: Body mass index; CAP: Controlled attenuated parameter; LS IQR: Liver
stiffness interquartile range.
high CAP values. Although a “high CAP cutoff value” had yet to be defined, the
cutoff for the high CAP tertile in this study was 330-340 dB/m.
Two prospective cohort studies on the natural history of NAFLD proposed that the
severity of liver fibrosis is the most important predictor of liver-related complications
as well as survival in patients with NAFLD[2,3]. In addition, recent studies suggested
that only the severity of fibrosis is an important prognostic factor for NAFLD, and is
independent  of  NASH  and  the  severity  of  inflammation [4 ,22].  These  studies
investigated the prognostic value of the baseline liver fibrosis stage, and one also
assessed the progression of liver fibrosis in patients with NAFLD[5]. Therefore, when
sequential liver biopsy is not practical, accurate prediction of fibrosis stage using
noninvasive  methods  is  important.  To  reduce  the  effect  of  hepatic  steatosis,  as
indicated by CAP scores, on the prediction of fibrosis based on LSM, we calculated
the cutoff  values for  significant  fibrosis  in  according to CAP tertile.  We applied
arbitrary CAP tertiles since the CAP score did not accurately differentiate S2 from S3
which  accounted  for  the  majority  of  the  patients.  Also,  CAP reportedly  cannot
differentiate adjacent grades of steatosis with high precision[23].  As a noninvasive
means of steatosis measurement, magnetic resonance imaging (MRI)-proton density
fat traction (PDFF) is reported to be more accurate for predicting hepatic steatosis
compared  to  CAP[24].  Magnetic  resonance  elastography  (MRE)  has  the  highest
diagnostic accuracy for staging fibrosis in patients with NAFLD. However, both MRI-
PDFF and MRE are MRI-based tools that require more space and more costly than
FibroScan with CAP[25].
Cutoff  values  according  to  CAP tertile  were  applied  to  estimate  the  effect  of
pioglitazone and UDCA on the LSM values at the 1-year follow up. Treatment with
pioglitazone reduced LSM-estimated proportion of significant fibrosis. However, the
CAP score did not change significantly after pioglitazone or UDCA administration. In
recent  NAFLD  practice  guidance,  pioglitazone  and  800  IU/day  vitamin  E  are
recommended to improve liver histology in patients with NASH[26]. The 184 patients
from which the LSM cutoff values for significant fibrosis were estimated included 130
patients treated with pioglitazone or UDCA. Although pioglitazone improved the
LSM value,  the  utility  of  this  result  is  limited  by  several  factors.  Ironically,  the
accuracy of  LSM cutoff  determined based on the CAP score cannot be validated
without follow-up biopsy after pioglitazone or UDCA treatment in patients with
NASH. Therefore,  studies involving paired liver biopsies are needed, until  more
reliable LSM standards for NAFLD are established. Secondly, being a retrospective,
observational study, the baseline demographic parameters of the pioglitazone and
UDCA-treated groups were not matched. Patients treated with pioglitazone were
more  likely  to  be  diabetic  and  hypertensive  which  are  important  elements  of
metabolic syndrome. Among NAFLD patients with fibrosis progression, 80% were
diabetic, suggesting that diabetes promotes the progression of NASH[5]. Although it
involved  a  larger  number  of  patients  with  diabetes,  our  study  showed  that
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Figure 2
Figure 2  Distribution of liver stiffness values within the same Kleiner fibrosis stages (F0-4) in different controlled attenuation parameter tertiles. A: F0-1; B:
F2; C: F3-4. CAP: Controlled attenuation parameter.
pioglitazone resulted in a  reduced proportion of  patients  with high LSM values
compared to UDCA. However,  the sample size was too small  to reach a definite
conclusion. Finally, unlike previous investigations of the effect of pioglitazone on
NASH, the patients in this study received low dose of pioglitazone (15 mg/day). Two
randomized studies of the effect of pioglitazone on NASH prescribed pioglitazone 30
mg or 45 mg daily to patients with NASH[27,28]. The mean BMIs of the patients in these
previous studies were about 33-35 kg/m2, compare to 29.2 ± 4.5 kg/m2 in this study,
and the lower dose of pioglitazone may have been effective due to the lower BMI of
our patients. Further studies investigating smaller doses of pioglitazone on patients
with NASH are needed to verify our results.
In conclusion, LSM in patients with NASH may overestimate the liver fibrosis
stage, particularly in those with high CAP values. Interpretation of LSM results taking
into  consideration  the  simultaneously  measured  CAP  scores  may  prevent  the
performance of unnecessary liver biopsy in patients with NAFLD.
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Table 3  Demographic, clinical, biochemical and histological characteristics of patients with nonalcoholic steatohepatitis under either
pioglitazone or ursodeoxycholic acid
Variable Pioglitazone group (n = 80) UDCA group (n = 50) P value
Age (yr) 47.6 ± 14.5 44.9 ± 14.5 0.303
Male gender 60 (75.0%) 30 (60.0) 0.071
Body mass index ≥ 25 kg/m2 66 (82.5%) 41 (82.0%) 0.942
Diabetes 38 (47.5%) 15 (30.0) 0.048a
Hypertension 29 (36.2%) 10 (20.0%) 0.049a
Hyperlipidemia 36 (45.0%) 26 (52.0%) 0.437
Fasting glucose (mg/dL) 121.3 ± 34.5 112.5 ± 24.1 0.090
HDL cholesterol (md/dL) 47.9 ± 10.0 47.7 ± 14.1 0.923
Triglycerides (mg/dL) 199.5 ± 147.7 185.9 ± 105.2 0.590
LDL cholesterol (mg/dL) 130.5 ± 29.4 136.4 ± 34.8 0.435
Alanine aminotransferase (U/L) 103.0 ± 76.1 74.6 ± 48.7 0.011a
Aspartate aminotransferase (U/L) 70.2 ± 40.5 65.7 ± 42.8 0.554
Gamma glutamyltransferase (U/L) 63.9 ± 61.3 62.3 ± 41.8 0.856
Platelet (× 1000/mm3) 229.8 ± 54.8 253.2 ± 54.4 0.019a
Albumin (g/dL) 4.5 ± 0.3 4.5 ± 0.3 0.866
Liver stiffness (kPa) 11.7 ± 4.8 10.5 ± 5.4 0.183
Stiffness IQR (kPa) 2.2 ± 4.7 1.4 ± 0.9 0.387
CAP (dB/m) 318.2 ± 37.9 319.3 ± 37.1 0.873
CAP IQR (dB/m) 25.2 ± 9.0 23.0 ± 10.1 0.216
Fibrosis score (Kleiner) 0.017a
F0 2 (2.5%) 9 (18.0%)
F1 41 (51.2%) 21 (42.0%)
F2 24 (30.0%) 15 (30.0%)
F3-4 13 (16.3%) 5 (10.0%)
Data are expressed as the mean ± standard deviation or median (range) or number (%),
aP < 0.05. UDCA: Ursodeoxycholic acid; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CAP: Controlled attenuation parameter; IQR:
Interquartile range.
Figure 3
Figure 3  False-positive rates when evaluating liver fibrosis stages by liver stiffness measurements. A: The cutoff of 8.95 kPa for detecting Kleiner fibrosis
stage (F) ≥ 2 was applied in all controlled attenuation parameter (CAP) tertiles; B: Different cutoffs were applied according to CAP tertiles. CAP: Controlled attenuation
parameter; LSM: Liver stiffness measurements.
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Figure 4
Figure 4  Change in the proportion of liver stiffness measurements predicting significant liver fibrosis, Kleiner fibrosis stage F ≥ 2, after 1-year of
pioglitazone or ursodeoxycholic acid treatment. A: In the lower controlled attenuation parameter (CAP) tertile; B: In the middle CAP tertile; C: In the high CAP
tertile. The liver stiffness measurements (LSM) cutoff values for F ≥ 2 are derived from the analysis 184 patients with biopsy proven nonalcoholic steatohepatitis after
considering different CAP scores in tertiles. The changes in LSM values are compared by paired t-test. CAP: Controlled attenuation parameter; LSM: Liver stiffness
measurements.
ARTICLE HIGHLIGHTS
Research background
In nonalcoholic  fatty liver disease (NAFLD),  studies demonstrate that  the severity of  liver
fibrosis is the most important determinant of the disease prognosis. Although liver biopsy is
considered the gold standard for identifying fibrosis stage, it is an invasive procedure, and liver
stiffness measurement (LSM) is widely preformed as a noninvasive means. However, LSM tends
to overestimate fibrosis stage in NAFLD.
Research motivation
Controlled attenuation parameter (CAP), provided by LSM device, has been introduced for
noninvasive  quantification  of  hepatic  steatosis.  It  also  has  been  suggested  that  CAP may
contribute in enhancing the accuracy of transient elastography measured LSM in patients with
NAFLD.
Research objectives
Our aim was to determine the role of CAP values in predicting liver fibrosis stages by LSM.
Research methods
This retrospective study involves 184 patients with biopsy proven nonalcoholic steatohepatitis
(NASH), seen at a tertiary hospital in Seoul, Republic of Korea between 2010 and 2017. These
patients had LSM and CAP evaluated within one month before the liver biopsy. Liver stiffness
and CAP scores were measured by the FibroScan (Echosens, Paris, France), a medical device,
using a standard probe. The patients in whom liver stiffness was measured when aspartate
aminotransferase or alanine aminotransferase level was more than fivefold the upper limit of
normal were excluded from the analysis due to the possibility of exacerbated LSM values. From
184 patients, 130 patients had 1-year follow-up LSM and analyzed for the changes of LSM after
pioglitazone or ursodeoxycholic acid (UDCA) treatment.
Research results
Among 184 NASH patients with liver biopsy, histologically assessed steatosis grade (S) was
distributed as follows: S1, n = 44 (2.9%); S2, n = 81 (44.0%); S3, n = 59 (32.1%). CAP scores were
significantly different between S1 and S2-S3 (P < 0.001). However, no significant difference was
found between S2 and S3 (P = 0.075). LSM significantly increased in accordance with the liver
biopsy detected fibrosis stage (P < 0.001). After multivariate analysis, CAP value along with
pathologically detected fibrosis stages was identified as a significant factor associated with LSM.
Since our assessment showed that no reliable cutoff was demonstrated to differentiate S3 from S2
and 76.1% (140/184) of our study patients were either S2 or S3, variations of LSM within the
same stage of liver fibrosis was evaluated according to the arbitrary CAP tertiles (lower 223-310,
middle 311-339, high 340-400 dB/m). In Kleiner fibrosis stage F0 - 1, LSM values increased at
high CAP tertile (P = 0.001), and in F2, at middle and high tertile (P = 0.027). No difference was
noticed in F3-4 (P = 0.752) according to CAP tertile. Receiver operating characteristic curves for
LSM cutoff in diagnosis of F ≥ 2 identified 8.05 kPa for lower CAP tertile, 9.35 kPa for middle,
and 10.55 kPa for high tertile. The patients treated with pioglitozone demonstrated decreased
LSM values after 1 year of the treatment (P < 0.001), when that in UDCA treated patients did not
show significant  changes  (P  =  0.068).  CAP values  did  not  show significant  changes  after
pioglitazone  (P  =  0.197)  or  UDCA  treatment  (P  =  0.057).  When  changes  in  proportion  of
significant fibrosis (F ≥ 2) were assessed among pioglitazone or UDCA treated patients reflecting
CAP values, pioglitazone treated patients demonstrated decrease in proportion of high LSM.
Research conclusions
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In conclusion, LSM in NASH may overestimate the liver fibrosis stage particularly in patients
with high CAP values. Interpretation of LSM considering simultaneously measured CAP scores
may provide more helpful information preventing unnecessary liver biopsy in patients with
NAFLD.
Research perspectives
In patients with NAFLD with high CAP scores, LSM cutoff that leads to liver biopsy may need to
be set higher than in those with other chronic liver diseases. Validation studies for more precise
LSM cutoffs should be performed incorporating larger number of patients with biopsy proven
NAFLD. With more reliable LSM cutoffs for noninvasive diagnosis of liver fibrosis in NAFLD,
clinical studies evaluating efficacies of treatment would be more widely preformed in NAFLD.
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